Ranbaxy launches Caduet authorized generic

Drug maker launches authorized generic under agreement with Pfizer; Mylan launched generic Thursday

PRINCETON, N.J. — Days after its launch of a generic version of Pfizer's cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.

Ranbaxy announced the launch of an authorized generic version of Caduet (atorvastatin and amlodipine besylate). The drug is used to treat patients with high blood pressure and high cholesterol. Mylan launched a generic version of the drug on Thursday.

An authorized generic is a branded drug launched under its generic name at a reduced price, usually by a third-party company under contract with the original manufacturer, to coincide with the marketing of the Food and Drug Administration-approved generic.

Caduet had sales of $339 million during the 12-month period ended in September, according to IMS Health.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.